| # | % | |||||
|---|---|---|---|---|---|---|
| 51 | ALNYLAM PHARMACEUTICALS INC | 40,000 | 3,214,000 | 0.41% | ||
| 52 | FORWARD PHARMA A/S | 135,000 | 3,181,000 | 0.41% | ||
| 53 | KITE PHARMA INCORPORATED | 56,970 | 3,172,000 | 0.40% | ||
| 54 | CARA THERAPEUTICS INC | 219,800 | 3,141,000 | 0.40% | ||
| 55 | Arrowhead Pharma Inc | 540,000 | 3,110,000 | 0.40% | ||
| 56 | ARBUTUS BIOPHARMA CORP | 505,000 | 3,075,000 | 0.39% | ||
| 57 | INSMED INC | 165,000 | 3,064,000 | 0.39% | ||
| 58 | CYNAPSUS THERAPEUTICS INC | 188,930 | 3,059,000 | 0.39% | ||
| 59 | RETROPHIN INC | 150,000 | 3,039,000 | 0.39% | ||
| 60 | THERAPEUTICSMD INC | 512,500 | 3,003,000 | 0.38% | ||
| 61 | TJX COS INC NEW | 41,496 | 2,964,000 | 0.38% | ||
| 62 | ULTRAGENYX PHARMACEUTICAL INC COM | 30,700 | 2,957,000 | 0.38% | ||
| 63 | SPARK THERAPEUTICS INCORPORATED | 70,000 | 2,921,000 | 0.37% | ||
| 64 | INTERCEPT PHARMACEUTICALS INCORPORATED | 17,500 | 2,903,000 | 0.37% | ||
| 65 | VALEANT PHARMACEUTICALS INTL | 15,750 | 2,809,000 | 0.36% | ||
| 66 | EXELIXIS INC | 500,000 | 2,805,000 | 0.36% | ||
| 67 | FOAMIX PHARMACEUTICALS LTD | 380,000 | 2,785,000 | 0.36% | ||
| 68 | INOTEK PHARMACEUTICALS CORP | 295,000 | 2,773,000 | 0.35% | ||
| 69 | MIRATI THERAPEUTICS INC COM | 80,000 | 2,754,000 | 0.35% | ||
| 70 | IONIS PHARMACEUTICAL | 68,000 | 2,749,000 | 0.35% | ||
| 71 | PALATIN TECHNOLOGIES INC COM | 3,358,483 | 2,720,000 | 0.35% | ||
| 72 | FIVE PRIME THERAPEUTICS INC | 175,000 | 2,693,000 | 0.34% | ||
| 73 | Nivalis Therapeutics Inc | 201,720 | 2,616,000 | 0.33% | ||
| 74 | Catabasis Pharmaceuticals Inc | 327,476 | 2,595,000 | 0.33% | ||
| 75 | GENOCEA BIOSCIENCES INC | 377,200 | 2,584,000 | 0.33% | ||
| 76 | Biotie Therapies Corp. | 196,800 | 2,576,000 | 0.33% | ||
| 77 | CYTOKINETICS INC | 372,250 | 2,490,000 | 0.32% | ||
| 78 | MONDELEZ INTL INC | 59,475 | 2,490,000 | 0.32% | ||
| 79 | ACCELERON PHARMA INC | 100,000 | 2,490,000 | 0.32% | ||
| 80 | KERYX BIOPHARMACEUTICALS INCORPORATED | 700,000 | 2,464,000 | 0.31% | ||
| 81 | DYNAVAX TECHNOLOGIES CORP | 100,000 | 2,454,000 | 0.31% | ||
| 82 | ABEONA THERAPEUTICS INC | 600,000 | 2,430,000 | 0.31% | ||
| 83 | PARTNER COMMUNICATIONS | 617,951 | 2,416,000 | 0.31% | ||
| 84 | UNIQURE NV | 115,000 | 2,352,000 | 0.30% | ||
| 85 | ELLOMAY CAPITAL LIMITED | 221,097 | 2,335,000 | 0.30% | ||
| 86 | SCYNEXIS INC | 313,000 | 2,279,000 | 0.29% | ||
| 87 | Life Technologies Corp | 209,027 | 2,145,000 | 0.27% | ||
| 88 | SUMMIT THERAPEUTICS PLC | 205,200 | 2,136,000 | 0.27% | ||
| 89 | CEMPRA INC | 75,000 | 2,088,000 | 0.27% | ||
| 90 | IMMUNE DESIGN CORP | 170,000 | 2,074,000 | 0.26% | ||
| 91 | PROTHENA CORP PLC | 45,133 | 2,046,000 | 0.26% | ||
| 92 | AEGERION PHARMACEUTICALS INC | 150,000 | 2,040,000 | 0.26% | ||
| 93 | HALOZYME THERAPEUTICS INC | 150,000 | 2,015,000 | 0.26% | ||
| 94 | WABTEC CORP | 22,735 | 2,002,000 | 0.26% | ||
| 95 | RELYPSA INC | 107,000 | 1,981,000 | 0.25% | ||
| 96 | EPIZYME INC COM | 150,000 | 1,929,000 | 0.25% | ||
| 97 | SEATTLE GENETICS INC | 50,000 | 1,928,000 | 0.25% | ||
| 98 | TRILLIUM THERAPEUTICS INC | 147,000 | 1,915,000 | 0.24% | ||
| 99 | NOVARTIS A G | 20,000 | 1,838,000 | 0.23% | ||
| 100 | SAREPTA THERAPEUTICS INC | 55,000 | 1,766,000 | 0.23% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001178913-15-003433, filed 2015.11.16).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
